# Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

> **NCT00843310** · PHASE2 · TERMINATED · sponsor: **NYU Langone Health** · enrollment: 8 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide (Revlimid)
- **DRUG:** Melphalan
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT00843310
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Due to slow accrual
- **Last updated:** 2017-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00843310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00843310, "Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00843310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*